Actuation Indicator Trial in Patients With COPD
Public ClinicalTrials.gov record NCT00928746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD. The actuation indicator is integrated into mouthpiece of the ipratropium bromide HFA inhalation aerosol device. As part of Boehringer Ingelheim's program to qualify an actuation indicator for use with the ipratropium bromide HFA inhalation aerosol device, this study is intended to complement the results from the ongoing in-vitro studies.
Study identification
- NCT ID
- NCT00928746
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Jul 31, 2009
- Completion
- Not listed
- Last update posted
- Jul 1, 2014
Started 2009
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 244.2507.0107 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 244.2507.0106 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 244.2507.0102 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 244.2507.0104 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 244.2507.0105 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 244.2507.0103 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 244.2507.0101 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00928746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2014 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00928746 live on ClinicalTrials.gov.